{
    "root": "0f08ec01-fce9-498e-810e-f74ad4ff24b2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Glycopyrrolate",
    "value": "20250303",
    "ingredients": [
        {
            "name": "GLYCOPYRROLATE",
            "code": "V92SO9WP2I"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        }
    ],
    "indications": "glycopyrrolate indicated adults reduce symptoms peptic ulcer adjunct treatment peptic ulcer . limitations glycopyrrolate indicated monotherapy treatment peptic ulcer effectiveness peptic ulcer healing established .",
    "contraindications": "important dosing information ( 2.1 ) \u2022 glycopyrrolate tablets 2 mg recommended patients initiating treatment receiving maintenance treatment glycopyrrolate tablets 1 mg another 1 mg strength oral glycopyrrolate tablets . recommended ( 2.2 ) \u2022 recommended initial glycopyrrolate tablets 1 mg 1 mg three times daily ( morning , early afternoon , bedtime ) . patients may require 2 mg bedtime assure overnight control symptoms . maintenance , 1 mg twice day frequently adequate . \u2022 recommended glycopyrrolate tablets 2 mg adults 2 mg two three times daily equally spaced intervals . \u2022 maximum recommended daily 8 mg. \u2022 lowest effective glycopyrrolate control symptoms . patients titrated lower dose , switch glycopyrrolate tablets 2 mg glycopyrrolate tablets 1 mg another 1 mg oral tablet glycopyrrolate .",
    "warningsAndPrecautions": "glycopyrrolate tablets usp , 1 mg white off-white , round , flat beveled edge tablet debossed \u201c mcr 117 \u201d separated break line one side plain side . packaged : carton 100 tablets ( 10 tablets blister pack x 10 ) , ndc 0904-6709-61 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 c 30\u00b0c ( 59\u00b0 f 86\u00b0f ) [ usp controlled room temperature ] . keep reach children . dispense tight container .",
    "adverseReactions": "glycopyrrolate tablets contraindicated : \u2022 patients risk anticholinergic toxicity due underlying medical condition , including : oglaucoma [ ( 5.1 ) ] oobstructive uropathies , including prostatic hypertrophy omechanical obstructive diseases gastrointestinal tract ( e.g . , pyloroduodenal stenosis , strictures ) [ ( 5.2 ) ] ogastrointestinal motility disorders ( e.g . , achalasia , paralytic ileus , intestinal atony ) [ ( 5.3 ) ] obleeding gastrointestinal ulcer oactive inflammatory infectious colitis lead toxic megacolon ohistory current toxic megacolon omyasthenia gravis \u2022patients hypersensitivity glycopyrrolate inactive ingredients glycopyrrolate tablets [ ( 6 ) description ( 11 ) ] .",
    "indications_original": "Glycopyrrolate is indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.\u00a0\u00a0\n                     \n                     Limitations of Use\n                      Glycopyrrolate is not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.",
    "contraindications_original": "Important Dosing Information ( 2.1 ) \u2022 Glycopyrrolate tablets 2 mg are not recommended for patients initiating treatment or receiving maintenance treatment with glycopyrrolate tablets 1 mg or another 1 mg dosage strength of oral glycopyrrolate tablets. Recommended Dosage ( 2.2 ) \u2022 The recommended initial dosage of glycopyrrolate tablets 1 mg is 1 mg three times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms. For maintenance, a dosage of 1 mg twice a day is frequently adequate. \u2022 The recommended dosage of glycopyrrolate tablets 2 mg for adults is 2 mg two or three times daily at equally spaced intervals. \u2022 The maximum recommended daily dosage is 8 mg. \u2022 Use the lowest effective dosage of glycopyrrolate to control symptoms. If patients can be titrated to a lower dose, switch from glycopyrrolate tablets 2 mg to glycopyrrolate tablets 1 mg or another 1 mg oral tablet of glycopyrrolate.",
    "warningsAndPrecautions_original": "Glycopyrrolate Tablets USP, 1 mg are white to off-white, round, flat beveled edge tablet debossed with \u201cMCR 117\u201d separated by break line on one side and plain on other side. Packaged:\n                  Carton of 100 tablets (10 tablets each blister pack x 10), NDC 0904-6709-61\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 C to 30\u00b0C (59\u00b0 F to 86\u00b0F) [see USP Controlled Room Temperature]. Keep out of reach of children.\n                      Dispense in tight container.",
    "adverseReactions_original": "Glycopyrrolate tablets are contraindicated in:\n                  \n                     \n                        \u2022\u00a0Patients at risk for anticholinergic toxicity due to an underlying medical condition, including:\n                           \n                              oGlaucoma [\n                                 see Warnings and Precautions (5.1)\n                              ]\n                           \n                              oObstructive uropathies, including prostatic hypertrophy\n                           \n                              oMechanical obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis, strictures) [\n                                 see Warnings and Precautions (5.2)\n                              ]\n                           \n                              oGastrointestinal motility disorders (e.g., achalasia, paralytic ileus, intestinal atony) [see Warnings and Precautions (5.3)]\n                           \n                           \n                              oBleeding gastrointestinal ulcer \n                           \n                              oActive inflammatory or infectious colitis which can lead to toxic megacolon \n                           \n                              oHistory of or current toxic megacolon \n                           \n                              oMyasthenia gravis\u00a0\n                        \n                     \n                     \n                        \u2022Patients with a hypersensitivity to glycopyrrolate or any of the inactive ingredients in glycopyrrolate tablets [\n                           see Adverse Reactions (6) and Description (11)\n                        ]."
}